{
  "docId": "019de071-be30-70fc-a858-8f20c51da6b3",
  "docSlug": "a62013e96cbc38ce4e129c5b57bb4496",
  "documentTitle": "Chimerix | Investor Conference Presentation Deck | 32 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 32,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The chart uses bubble plots to represent survival probability distributions across different studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-be30-70fc-a858-8f20c51da6b3/25",
  "deckHref": "/decks/019de071-be30-70fc-a858-8f20c51da6b3",
  "deckJsonHref": "/decks/019de071-be30-70fc-a858-8f20c51da6b3.json",
  "deckAnchorHref": "/decks/019de071-be30-70fc-a858-8f20c51da6b3#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.42,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Recurrent glioma historic survival",
      "attrs": null,
      "subkind": "bubble",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea218761-b78d-41dc-9a91-b0327fac57e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.06,
        "y": 0.16
      },
      "kind": "list",
      "text": "H3 K27M-mutant DMG is a grade IV by WHO; FDA has acknowledged available therapy is palliative; Survival in grade II-IV recurrent glioma reported to be 27.5% at 12 months and 6.4% at 24 months; Survival in pediatric recurrent H3 K27M DMG reported to be 0% at 24 months; Survival in ONC201-treated recurrent H3 K27M DMG was 57% OS at 12 months and 35% at 24 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbb85a4f-2596-4333-b37f-fc3746d539ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.1,
        "y": 0.09
      },
      "kind": "source-note",
      "text": "1. Data collected from 15 literature sources since 2010 with trial arms size >30 pts each reporting data on 1816 pts with recurrent, unstratified disease. 2. 10 literature sources that describes OS with 1279 patients 3. Koschmann et al, 2020; DOI:10.21203/rs.3.rs-69706/v1",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c112a7b5-b271-46d8-999a-ff38490bbc62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.64,
        "x": 0.18,
        "y": 0.06
      },
      "kind": "title",
      "text": "Recurrent Glioma Remains a High Unmet Need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "771e733b-7014-48a0-a249-cb8b1f3d9b8e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "b3bd5a96-22e8-417b-92e2-e13854cbf533",
      "evidence": "Recurrent Glioma Remains a High Unmet Need",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 25,
      "beatId": "9038b9a7-aadf-4677-ac42-4825c9616f63",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problem by highlighting the high unmet need",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 32,
      "from": 22,
      "beatId": "b94e1c59-1634-4aae-b2ea-f66697bc962f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides a solution in the form of ONC201's clinical efficacy",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6564a4a4-69c2-4b9e-bfb9-d55b5f1c4163",
      "evidence": "The presentation highlights the high unmet need",
      "position": 0,
      "objective": "Highlight the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}